Page 60 - 2020_02-Haematologica-web

R. Vilar et al.
References
1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fib- rinogen and fibrin. Ann N Y Acad Sci. 2001;936:11-30.
2. Standeven KF, Ariens RA, Grant PJ. The molecular physiology and pathology of fib- rin structure/function. Blood Rev. 2005;19(5):275-288.
3. FishRJ,Neerman-ArbezM.Fibrinogengene regulation. Thromb Haemost. 2012;108(3): 419-426.
4. Espitia Jaimes C, Fish RJ, Neerman-Arbez M. Local chromatin interactions contribute to expression of the fibrinogen gene cluster. J Thromb Haemost. 2018;16(10):2070-2082.
5. Fort A, Fish RJ, Attanasio C, et al. A liver enhancer in the fibrinogen gene cluster. Blood. 2011;117(1):276-282.
6. Vorjohann S, Pitetti J-L, Nef S, et al. DNA methylation profiling of the fibrinogen gene landscape in human cells and during mouse and zebrafish development. PLoS One. 2013;8(8):e73089.
7. Fort A, Borel C, Migliavacca E, et al. Regulation of fibrinogen production by microRNAs. Blood. 2010;116(14):2608- 2615.
8. Lukowski SW, Fish RJ, Martin-Levilain J, et al. Integrated analysis of mRNA and miRNA expression in response to interleukin-6 in hepatocytes. Genomics. 2015;106(2):107- 115.
9. Redman CM, Xia H. Fibrinogen biosynthe- sis. Ann N Y Acad Sci. 2001;936 (1):480-495.
10. Vu D, Di Sanza C, Caille D, et al. Quality control of fibrinogen secretion in the molec- ular pathogenesis of congenital afibrinogen- emia. Hum Mol Genet. 2005;14(21):3271-
3280.
11. Bleyer WA, Hakami N, Shepard TH. The
development of hemostasis in the human fetus and newborn infant. J Pediatr. 1971;79(5):838-853.
12. Brown AC, Hannan RT, Timmins LH, et al. Fibrin network changes in neonates after cardiopulmonary bypass. Anesthesiology. 2016;124(5):1021-1031.
13. Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem. 2017;82:405-456.
14. Macrae FL, Duval C, Papareddy P, et al. A fibrin biofilm covers blood clots and protects from microbial invasion. J Clin Invest. 2018;128(8):3356-3368.
15. Ko Y-P, Flick MJ. Fibrinogen Is at the inter- face of host defense and pathogen virulence in staphylococcus aureus infection. Semin Thromb Hemost. 2016;42(4):408-421.
16. FurieB,FurieBC.Mechanismsofthrombus formation. N Engl J Med. 2008;359(9):938- 949.
17. SmithSA,TraversRJ,MorrisseyJH.Howit all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326- 336.
18. Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al., eds. Williams Hematology, 9e. New York, NY: McGraw-Hill Education, 2015.
19. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595.
20. Casini A, Blondon M, Tintillier V, et al. Mutational epidemiology of congenital fib- rinogen disorders. Thromb Haemost.
2018;118(11):1867-1874.
21. Vu D, Neerman-Arbez M. Molecular mech-
39. Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125(3):553-
anisms accounting for fibrinogen deficiency:
from large deletions to intracellular retention 561.
of misfolded proteins. J Thromb Haemost.
2007;5 (Suppl 1):125-131.
22. Rabe F, Salomon E. Ueber-faserstoffmangel
im Blute bei einem Falle von Hämophilie.
Ann Intern Med. 1920;95:2-14.
23. Neerman-Arbez M, Antonarakis SE,
Honsberger A, et al. The 11 kb FGA deletion responsible for congenital afibrinogenaemia is mediated by a short direct repeat in the fibrinogen gene cluster. Eur J Hum Genet. 1999;7(8):897-902.
24. Neerman-Arbez M, Honsberger A, Antonarakis SE, et al. Deletion of the fib- rinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogene- mia. J Clin Invest. 1999;103(2):215-218.
25. Lak, Keihani, Elahi, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107(1):204-206.
26. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early pre- dictor of the severity of postpartum hemor- rhage. J Thromb Haemost. 2007;5(2):266- 273.
27. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106(3):385-392.
28. Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003;89(1):9- 12.
29. Korte W, Poon M-C, Iorio A, et al. Thrombosis in inherited fibrinogen disor- ders. Transfus Med Hemother. 2017;44 (2):70-76.
30. Litvinov RI, Weisel JW. What is the biologi- cal and clinical relevance of fibrin? Semin Thromb Hemost. 2016;42(4):333-343.
31. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2019;133(5):415-424.
32. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-defi- cient mice. Genes Dev. 1995;9(16):2020- 2033.
33. Degen JL, Drew AF, Palumbo JS, et al. Genetic manipulation of fibrinogen and fib- rinolysis in mice. Ann N Y Acad Sci. 2001;936:276-290.
34. Fish RJ, Di Sanza C, Neerman-Arbez M. Targeted mutation of zebrafish fga models human congenital afibrinogenemia. Blood. 2014;123(14):2278-2281.
35. Hu Z, Lavik KI, Liu Y, et al. Loss of fibrino- gen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia. J Thromb Haemost. 2019;17(4):607-617.
36. Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci. 2017;18(12):2711.
37. Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16 (9):1887-1890.
38. Casini A, Neerman-Arbez M, Ariens RA, et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13(6): 909-919.
40. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis- induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994.
41. Chang H, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88(4):321-328.
42. Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016;7:217-225.
43. Levy JH, Goodnough LT. How I use fibrino- gen replacement therapy in acquired bleed- ing. Blood. 2015;125(9):1387-1393.
44. Kolev K, Longstaff C. Bleeding related to dis- turbed fibrinolysis. Br J Haematol. 2016;175(1):12-23.
45. CRASH-2 Trial Collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with signifi- cant haemorrhage (CRASH-2): a ran- domised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
46. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116.
47. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to glob- al disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363-2371.
48. Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. 2017;130(16):1795-1799. 49. Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular dis- ease: the Framingham Study. JAMA.
1987;258(9):1183-1186.
50. Meade TW, Chakrabarti R, Haines AP, et al.
Hæmostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;315(8177):1050-1054.
51. Wilhelmsen L, Svärdsudd K, Korsan- Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311(8):501-505.
52. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta- analysis. JAMA. 2005;294(14):1799-1809.
53. Zhang Y, Zhu C-G, Guo Y-L, et al. Higher fibrinogen level is independently linked with the presence and sseverity of new- onset coronary atherosclerosis among Han Chinese population. PLoS One. 2014;9(11): e113460.
54. Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrino- genemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011;117(18): 4953-4963.
55. Lowe GDO. Fibrinogen assays for cardio- vascular risk assessment. Clin Chem. 2010;56(5):693-695.
56. Sarker H, Hardy E, Haimour A, et al. Identification of fibrinogen as a natural inhibitor of MMP-2. Sci Rep. 2019;9 (1):4340.
57. Sabater-Lleal M, Huang J, Chasman D, et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but
294
haematologica | 2020; 105(2)